- Home
- MRSN vs CBAT Comparison
MRSN vs CBAT Comparison
Compare MRSN & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- CBAT
- Stock Information
- Founded
- MRSN 2001
- CBAT 1999
- Country
- MRSN United States
- CBAT China
- Employees
- MRSN N/A
- CBAT N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- CBAT Industrial Machinery/Components
- Sector
- MRSN Health Care
- CBAT Miscellaneous
- Exchange
- MRSN Nasdaq
- CBAT Nasdaq
- Market Cap
- MRSN 71.9M
- CBAT 71.6M
- IPO Year
- MRSN 2017
- CBAT N/A
- Fundamental
- Price
- MRSN $0.34
- CBAT $0.80
- Analyst Decision
- MRSN Buy
- CBAT
- Analyst Count
- MRSN 3
- CBAT 0
- Target Price
- MRSN $4.00
- CBAT N/A
- AVG Volume (30 Days)
- MRSN 3.1M
- CBAT 156.5K
- Earning Date
- MRSN 03-03-2025
- CBAT 03-17-2025
- Dividend Yield
- MRSN N/A
- CBAT N/A
- EPS Growth
- MRSN N/A
- CBAT N/A
- EPS
- MRSN N/A
- CBAT 0.13
- Revenue
- MRSN $40,497,000.00
- CBAT $176,614,609.00
- Revenue This Year
- MRSN N/A
- CBAT $28.79
- Revenue Next Year
- MRSN N/A
- CBAT $36.77
- P/E Ratio
- MRSN N/A
- CBAT $6.04
- Revenue Growth
- MRSN 9.88
- CBAT N/A
- 52 Week Low
- MRSN $0.34
- CBAT $0.77
- 52 Week High
- MRSN $4.64
- CBAT $2.08
- Technical
- Relative Strength Index (RSI)
- MRSN 29.11
- CBAT 38.88
- Support Level
- MRSN $0.41
- CBAT $0.77
- Resistance Level
- MRSN $0.42
- CBAT $0.90
- Average True Range (ATR)
- MRSN 0.04
- CBAT 0.05
- MACD
- MRSN -0.00
- CBAT -0.00
- Stochastic Oscillator
- MRSN 3.43
- CBAT 20.85
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.